Boston Scientific has agreed to acquire Penumbra in a deal worth around $14.5bn, a move that will expand the medtech giant’s offerings in ‘fast-growing segments’ within the vascular care space. Under the deal, Boston will inherit Penumbra products, including the US company’s Lightning Bolt and Lightning Flash computer-assisted vacuum thrombectomy (CAVT) systems for removing blood clots in the arterial, venous and pulmonary vessels. The systems received US Food and Drug Administration (FDA) clearance in 20 ...

Boston Scientific on Thursday announced plans to acquire Penumbra, a US-based thrombectomy specialist, in a cash-and-stock deal valued at about $14.5 billion, marking one of the largest transactions in the global medical technology sector this year. The acquisition is aimed at strengthening Boston Scientific's cardiovascular and vascular intervention portfolio, as the company looks to capitalise on rising demand for minimally invasive treatments for blood clots, stroke and other life-threatening conditions. ...

Core Viewpoint - Penumbra has demonstrated strong share price performance, increasing by 35.9% over the past year, significantly outperforming the industry which saw a decline of 13.3% [1] Company Performance - Penumbra's thrombectomy business is experiencing robust growth, with a year-over-year increase of 25% in the first quarter of 2025, driven by the adoption of its CAVT portfolio and new product launches [5] - The international thrombectomy revenues grew by 18.2% year-over-year, particularly strong in regions outside China, indicating potential for future growth [6] - The company has a solid financial position, exiting the first quarter of 2025 with cash and cash equivalents of $379 million, an increase from $340 million in the previous quarter [7] Product Development and Market Adoption - The growth in share price is attributed to consistent revenue growth, particularly from the Lightning Flash and Lightning Bolt product lines, which have shown extraordinary patient outcomes [4] - The recent launch of the RED 72 catheter has received positive clinical uptake, reinforcing Penumbra's leadership in stroke care [5] Future Projections - The Zacks Consensus Estimate predicts a 69.8% increase in earnings per share (EPS) for 2025, with revenues projected to grow by 13.4% to $1.35 billion [11]